Zacks small cap research.

Raises Gross Proceeds of $55 Million to Advance Lead Compound to Clinical Trials. On My 17, 2023, Satellos Biosciences Inc. (OTC:MSCLF) announced it closed an equity offering in which it raised gross proceeds of $55 million from the issuance of 110 million equity securities at $0.50 per common share or pre-funded warrant (70,297,220 common ...Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted results from its Ongoing Research of Cytisinicline for Addiction, Vaping (ORCA-V1) trial and hosted a conference call for investors on April 20, 2023. The Phase II ORCA-V1 trial was conducted to measure the safety and effectiveness of 3 mg of cytisinicline dosed three times daily for 12 weeks ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Nine analysts revised their earnings estimate higher in the last 60 days for fiscal 2023, while the Zacks Consensus Estimate has increased $0.78 to $16.84 per …Put on Your Rally Cap, as We Turn the Last Two Inside-Out Do you get the sense that folks were more bullish after last Wednesday's rally than they were after Monday's rally? That's the sense I get. I suppose that is because last week's rug ...

Apr 7, 2022 · YY. 40.15. +4.02%. A complete archive of Small-cap articles from Zacks Investment Research. Our Research, Your Success. Sep 14, 2023 · Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. _____ 1. BioLineRx Corporate Website, Accessed September 2023.

David Bautz, PhD, Senior Analyst for Zacks Small-Cap Research, with 9 years of direct experience in the securities and investment industry. David’s research articles have been posted extensively on Yahoo Finance News and throughout life sciences social media circles. Prior to joining Zacks in 2014, David was an NRSA postdoctoral fellow ... Nov 10, 2023 · LGVN Continues to Show Progress. Longeveron (NASDAQ:LGVN) released its 3Q earnings results: • Revenues of $200,000, which was slightly lower than last year due to completion of some grant-funded trials. • Earnings per share of -$0.28, which is in the range of what we were expecting. During 3Q 2023, Longeveron completed a direct offering of ...

Zacks Equity Research November 23, 2023. CVX Quick Quote CVX ... Overall, they are usually a stable option, with less risk and more sure-fire cash flows than …Aug 24, 2023 · By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update HyBryte™ Expanded Treatment Trial Underway On August 10, 2023, Soligenix, Inc. (NASDAQ:SNGX) announced the start of the investigator-initiated study that is designed to examine the expanded treatment, including up to 12 months of treatment, with HyBryte in patients with early-stage cutaneous T cell lymphoma ... SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …ARDS is a serious lung disorder that results from the small blood vessels of the lung leaking fluid that fills up the alveoli, thus preventing proper oxygen exchange (Stevens et al., 2018). There are many causes of ARDS, including infections (e.g., pneumonia), severe burns, pancreatitis, inhalation of smoke or chemicals, or other …

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research. Read full article. Gain Therapeutics, Inc. December 4, 2023 at …

Zacks Small-Cap Research Sponsored – Impartial – Comprehensive November 8, 2023 John D. Vandermosten, CFA scr.zacks.com 312-265-9588 / [email protected] …Apr 18, 2023 · By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT We are initiating coverage of Abeona Therapeutics Inc. (NASDAQ:ABEO) with a valuation of $10.00. Abeona is a biopharmaceutical company developing cell and gene therapies for rare genetic diseases. Its lead clinical program, EB-101, is an autologous cell therapy in development for the treatment of recessive dystrophic epidermolysis Zacks Small-Cap Research Sponsored – Impartial – Comprehensive November 8, 2023 John D. Vandermosten, CFA scr.zacks.com 312-265-9588 / [email protected] …5 Aug 2021 ... Zacks Small-Cap Research. Sponsored – Impartial - Comprehensive scr ... Cap Research (“Zacks SCR”), a division of Zacks Investment Research.SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …LEXX: GLP-1s’ Sweet Opportunity. Lexaria Bioscience Corporation (NASDAQ:LEXX) reports fiscal full year 2023 results along with program updates, new deals and a small capital raise since the third quarter report in August. The company announced that the investigational new drug (IND) application would be delayed on account of a supplier.Research Reports. Companies by Analyst. Steven Ralston, CFA; David Bautz, PhD; Ann Heffron, CFA, CPA; Thomas Kerr, CFA; Brian Lantier, CFA; M. Marin; Brad Sorensen, …

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …By M. Marin NASDAQ:NVX | OTC:NVNXF READ THE FULL NVX RESEARCH REPORT Company positioning to benefit from ramping growth in target verticals Novonix (NASDAQ:NVX) (OTC:NVNXF) has a positive sector tailwind, in our opinion, as it advances its strategy to develop a U.S.-based lithium-ion battery materials …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Zacks Small Cap Research coverage specifically looks to focus on small and micro-cap companies that are under followed or under valued by Wall Street. Our analysts seek to identify and report...Update on Phase 1 Trial of EPI-7386. ESSA Pharma Inc. (NASDAQ:EPIX) is currently conducting a Phase 1 clinical trial of EPI-7386 in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed on two or more systemic therapies, including at least one second generation anti-androgen therapy ( NCT04421222 ).

On November 19, 2023, MediciNova, Inc. (NASDAQ:MNOV) announced new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

Steven Ralston, CFA, is a Senior Analyst and Director of Research with Zacks Small-Cap Research, with over 30 years of experience in the securities and investment industry. He has covered companies within the Basic/Precious Materials, Industrials, Energy, Biotechnology, Real Estate, Cannabis, Packaged Foods, Consumer and Financial …On January 17 th, electroCore announced preliminary 4Q:22 revenues of $2.5 million, which is ahead of our $2.2 million expectation. For 2022, revenues were $8.5 million, a 57% increase over 2021 levels. Strength in government channels, which produced a 56% increase were surpassed in percentage terms by growth in commercial which saw a …Aug 24, 2023 · By Lisa Thompson OTC:NEXCF CSE:TGGL READ THE FULL NEXCF RESEARCH REPORT Nextech (OTC:NEXCF) reported Q2 revenues of $1.4 million, up $100,000 sequentially from Q1 and 153% from Q2 2022. The company had preannounced this number on August 1st. Investors are still awaiting news that Nextech’s 3D modeling services will be available to merchants in Amazon’s Seller Central which is expected to boost SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …ARDS is a serious lung disorder that results from the small blood vessels of the lung leaking fluid that fills up the alveoli, thus preventing proper oxygen exchange (Stevens et al., 2018). There are many causes of ARDS, including infections (e.g., pneumonia), severe burns, pancreatitis, inhalation of smoke or chemicals, or other serious illnesses.By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 3Q:23 results on November 13, 2023 via its filing of Form 10-Q with the SEC. Since the filing of the second quarter 10-Q in mid-August, the company has finished compiling and submitting its investigational new drug (IND)SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

Zacks Small-Cap Research Tom Kerr 312-265-9147 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 November 14, 2022 UPDATE: Siyata reported 2022 3rd quarter financial results which showed high revenue growth rates compared to the prior year period. Utilizing a DCF valuation process containing

Zacks Small Cap Research Coverage Universe. For access to our most recent reports, please click on the links below. To join our paid real time email service please enter your email address and select the companies you would like to follow. An email will be sent to you for payment and setup instructions. Special Situations / Steven Ralston, CFA.

Nov 16, 2023 · Net R&D expenses for the third quarter of 2023 were $3.3 million, compared to $3.8 million during the third quarter of 2022. The decrease was primarily due to decreased costs related to the Phase 3 clinical trial and decreased payroll expense, travel, materials, depreciation, and other activities. G&A expenses for the third quarter of 2023 were ... The small-cap index Russell 2000 recently witnessed its most impressive week in over two years as investors bet on the Federal Reserve's halt in its interest rate …By Brad Sorensen, CFA OTC:PBSV READ THE FULL PBSV RESEARCH REPORT Pharma-Bio Serv (OTC:PBSV) announced 2Q 2023 results. The headline showed that earnings per share of $0.02 were inline with our estimates, driven by the continued impressive improvement in gross margin on sales revenue by another 5% in the quarter …$31.77 USD -0.10 (-0.31%) Zacks MF Rank NA View All Zacks Mutual Fund Rank #1's Zacks Mutual Funds Categories » Small Cap Blend Latest Performance as of Oct 31, 2023 * Annual for three...LEXX: GLP-1s’ Sweet Opportunity. Lexaria Bioscience Corporation (NASDAQ:LEXX) reports fiscal full year 2023 results along with program updates, new deals and a small capital raise since the third quarter report in August. The company announced that the investigational new drug (IND) application would be delayed on account of a supplier.LEER has been making truck accessories since the late 1960s, and LEER fiberglass truck caps dominate the truck cap industry in both Canada and the US, according to Cap World. These fiberglass truck caps are lightweight and known for fitting...Nov 22, 2023 · Research and development expenses in the 3rd quarter of 2023 were $469,000 which was similar to R&D expenses in the 3rd quarter of 2022 of $468,000. R&D expenses include the use of third-party contractors for further R&D activities, the performance of usability studies for the PressureSafe device, and non-cash expenses relating to stock-based ... Sep 2, 2022 · Results from the second bioequivalence study were shared with investors a few weeks ago on August 22, 2022. The data demonstrated pharmacokinetic equivalence between 5 mg of Alpha-1062 delayed release tablets and 8 mg galantamine hydrobromide extended release (ER) capsules. These results combined with the data released in June show that both ...

By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT Fiscal Year 2022 Financial Results On December 28, 2022, CEL-SCI Corporation (NYSE:CVM) submitted its fiscal year 2022 Form 10-K with the SEC concurrent with a press release announcing fiscal year 2022 results. ... SUBSCRIBE TO ZACKS SMALL CAP …The details of 2Q 2023: • Revenue for the quarter came in at $1,480,388, which was more than double the revenue seen in the previous quarter of just over $625,000. • FRX posted a quarterly loss of $0.02 per share, slightly ahead of our estimates due largely to an improvement in the gross margin. • Gross margins improved to a gain of ...The small-cap index Russell 2000 recently witnessed its most impressive week in over two years as investors bet on the Federal Reserve's halt in its interest rate …Instagram:https://instagram. dividend payment datesblackstone etfbest real estate investing appfidelity vs webull GBS: Glucose Biosensor Trial IRB Approval. 04/04/2022. Download (opens in new window) PDF 555 KBZacks Rank N/A BIOR: Precision Release – Surgical Strike on the GI Tract Zacks Small-Cap Research Joh Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. … mutual funds with highest dividendsblue bridle insurance agency © Zacks Small Cap Research - All rights reserved Powered By Q4 Inc. 5.111.2.6 (opens in new window) 5.111.2.6 (opens in new window) By Lisa Thompson NASDAQ:GROM Fresh off a December $5.0 million capital raise and reverse split in December, Grom Social Enterprises (NASDAQ:GROM) is poised to capitalize on a number of promising initiatives over the next several months. The company now has 3.2 million in fully diluted shares and trades at a market capitalization … how much can i sell my xbox 360 for SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Zacks Small-Cap Research Spo nsored – Impartial - Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 November 30, 2022 Lisa Thompson 312-265-9154 / [email protected] ... Zacks Inves tment Research Page 3 scr.zacks.com mainly related to capital markets consulting fees incurred as Tenet plans to list its ...